FIG 6.

Rabbits developed undetectable or low mucosal antibody responses to all of the prime/boost regimens. New Zealand White rabbits received a priming immunization of MVAgp120 either i.m. or i.n. in week 0 and gp120 boosts i.m. and/or i.n. in weeks 12 and 16. Feces were collected from all individuals (n = 4 to 6/group), and vaginal lavage was performed on the females (n = 3 or 4/group). The results shown are from week 19, 3 weeks after administration of the second booster vaccine. (A) Fifty to 100% of the rabbits in each group developed detectable fecal gp120-specific IgG titers. (B) Twenty-five to 50% of the rabbits in each group developed fecal gp120-specific IgA titers. (C) Vaginal gp120-specific IgG was detectable in 50 to 100% of the female rabbits in each group but tended to be lower than the fecal gp120-specific IgG titers observed. (D) Vaginal gp120-specific IgA was detectable in only 2 of the 4 i.m./i.n.-vaccinated females. The horizontal lines indicate the geometric mean titers.